ReveraGen BioPharma
Dr. van den Anker is a pediatric clinical pharmacologist and authority in pediatric and neonatal clinical drug trials. He is actively involved in pediatric clinical pharmacology programs in both the USA (Children’s National Medical Center, Washington, DC and Johns Hopkins University, Baltimore, MD) and Europe (University of Basel Children’s Hospital, Basel, Switzerland and Erasmus Medical Center-Sophia Children’s Hospital in Rotterdam, the Netherlands). Dr. van den Anker was appointed as CMO in 2017 and he will split his time between his research positions in Basel and Washington and supporting ReveraGen as CMO.
This person is not in any teams
This person is not in any offices
ReveraGen BioPharma
ReveraGen BioPharma is a small clinical-stage drug development company with a focus on developing therapeutics.